ESR2 and Hepatic fibrosis: Kehui Zhang et al. [135] established a wild-type and ERKO mouse liver fibrosis model, demonstrating that SS-d can inhibit the ROS/NLRP3 inflammasome axis through the activation of the ERβ pathway, thereby alleviating liver fibrosis.